Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416571 | 0.85 | DPP4 (0.38) | RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL416781 | 0.84 | RPA1 (0.34) | RAB9ANPC1MEN1KMT2ABRAF | |
| SCHEMBL418233 | 0.83 | HSP90AA1 (0.40) | RAB9ASMN1; SMN2BRAF | |
| SCHEMBL419511 | 0.82 | RPA1 (0.35) | RAB9ANPC1SMN1; SMN2BRAF | |
| SCHEMBL417818 | 0.81 | RPA1 (0.53) | RAB9ANPC1KDM4EMDM2ALDH1A1 | |
| SCHEMBL417954 | 0.75 | ALOX5 (0.40) | RAB9ANPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL421428 | 0.75 | PRKDC (0.42) | RAB9ANPC1SMN1; SMN2BRAFALDH1A1 | |
| SCHEMBL419740 | 0.73 | PGR (0.34) | BRAF | |
| SCHEMBL421270 | 0.72 | PDE4B (0.40) | RAB9ASMN1; SMN2MEN1KMT2ABRAF | |
| SCHEMBL2486902 | 0.72 | RPA1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376479-B1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010075957-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AADAC, DDC, TPMT | RAB9A 4238/4885NPC1 2894/4885SMN1; SMN2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.